Telormedix Presents at the Biotech Showcase in San Francisco

Bioggio, Switzerland, 9th January 2013 - Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, will present today at the Biotech Showcase 2013 in San Francisco, CA. Johanna Holldack, Telormedix’s Chief Executive Officer, will give a presentation on the status of the Company’s drug pipeline.

The Telormedix presentation is scheduled for Wednesday, 9th January 2013 at 11:30 AM (Pacific Standard Time) in Track A, in room “Hearst”. The Company presentation will take place at the Hotel Parc 55 Wyndham San Francisco – Union Square.

About Telormedix

Telormedix (www.telormedix.com), founded in October 2007, is a biopharmaceutical company focused on targeted immunity and modulation of the innate immune system for treating cancer and autoimmune diseases. The Company’s lead product, TMX-101, recently entered a Phase I/II clinical trial for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). In addition, Telormedix is developing novel TLR7-targeted agonists. One of these molecules, TMX-202, has recently been selected for preclinical study for the topical treatment of skin cancers and other indications. Telormedix also has a pipeline of programs for inflammatory and autoimmune diseases, which includes TMX-302, a TLR7-binding small molecule showing anti-inflammatory properties in vivo.

Located in Switzerland, Telormedix is led by a highly experienced management team and backed by an international consortium of venture capitalists including Aravis Venture (Basel, Switzerland) and Proquest Investments (Princeton-San Diego, USA).

Further Information:

Johanna Holldack

CEO

Telormedix SA

t: +41 (0)91 610 7000

e: jholldack@telormedix.com

Robert Mayer

Account Director

College Hill Life Sciences

t : +49 (0)89 5238 8030

e: robert.mayer@collegehill.com